A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

British Journal of Cancer

Volumn 95, Issue 4, 2006, Pages 457-462

  Collins, R ^a   Trowman, R ^a   Norman, G ^a   Light, K ^a   Birtle, A ^b   Fenwick, E ^c   Palmer, S ^d   Riemsma, R ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

^e KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

Author keywords

Docetaxel; Hormone refractory prostate cancer; Mitoxantrone; Systematic review

Indexed keywords

CLODRONIC ACID; CORTICOSTEROID; DOCETAXEL; ESTRAMUSTINE; HYDROCORTISONE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIBLIOGRAPHIC DATABASE; BIOSIS; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFECT; DRUG EFFICACY; EMBASE; EVALUATION; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MEDLINE; METASTASIS; NEUTROPENIA; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MITOXANTRONE; NEOPLASM METASTASIS; PREDNISOLONE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33747186098     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603287     Document Type: Article

References (19)

1. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439-2443
2. Cabrespine A, Guy L, Chollet P, Fleury J, Gachon F, Curé H, Mouret-Reynier M, Van Praagh I, Penault-Llorca F, Bay J. Phase II study of paclitaxel carboplatin combination versus mitoxantrone in patients with hormone-refractory prostate cancer [conference abstract: no. 301]. In: 2005 Prostate Cancer Symposium. Alexandria, VA: American Society of Clinical Oncology
3. Cancer Research UK (2004) CancerStats incidence - UK [web page on the Internet] London: Cancer Research UK
4. Cell Genesys. GVAX® Prostate Cancer Vaccine vs Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer [web page on the Internet] Bethesda, MD: National Institutes of Health
5. Centre for Reviews and Dissemination (2001) Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for those Carrying out or Commissioning reviews [CRD report 4] CRD Reports. York: Centre for Reviews and Dissemination
6. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R (2006) A systematic review and economic model of the effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess (in press)
7. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634
8. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Thompson IM, Bueschen AJ, Lowe BA (1998) Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 339: 1036-1042
9. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21: 3335-3342
10. James N. A randomised phase II feasibility study of docetaxel (Taxotere) plus prednisolone vs docetaxel (Taxotere) plus prednisolone plus zoledronic acid (Zometa) vs docetaxel (Taxotere) plus prednisolone-+ zoledronic acid (Zometa) plus strontium-89 in HRPC. [Ongoing trial - ISRCTN12808747]
11. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506-2513
12. Kelly W (2005) Phase III Randomized Study of Docetaxel and Prednisone with versus without Bevacizumab in Patients with Hormone-Refractory Metastatic Adenocarcinoma of the Prostate [Patient Version] [Web Page on the Internet] Bethesda, Maryland: National Cancer Institute
13. Muthuramalingam SR, Patel K, Protheroe A (2004) Management of patients with hormone refractory prostate cancer. Clin Oncol (Royal College of Radiologists) 16: 505-516
14. National Institute for Clinical Excellence (2002) Guidance on Cancer Services: Improving Outcomes in Urological Cancers: the Manual. London: NICE
15. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon M-F, Andrieu J-M (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23: 3343-3351
16. Petrylak DP (2002) Chemotherapy for androgen-independent prostate cancer. Sem Urologic Oncol 20(3, Suppl 1): 31-35
17. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [SWOG 9916]. New Engl J Med 351: 1513-1520
18. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer [TAX 327]. New Engl J Med 351: 1502-1512
19. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CML, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764